Oligodendrocyte dysfunction drives age-related cognitive decline
Analysis based on 6 articles · First reported Aug 25, 2026 · Last updated Sep 07, 2026
The study highlights a potential new therapeutic target for age-related cognitive decline, which could drive investment in neurodegenerative disease research and drug development. Existing NRF2-activating drugs, such as those for multiple sclerosis, may be repurposed, potentially expanding their market and benefiting pharmaceutical companies involved.
A study published in Nature Medicine on August 25, 2026, reveals that oligodendrocytes, the brain cells that produce myelin, can become dysfunctional with age and actively contribute to cognitive decline. Researchers from the University of Edinburgh and the UK Dementia Research Institute analyzed brain tissue from the Lothian Birth Cohort 1936, finding that more severe cognitive decline was associated with fewer large nerve fibers and excess unhealthy myelin. They also observed reduced levels of the protein NRF2 in oligodendrocytes. Experiments in mice showed that disrupting NRF2 in these cells caused similar myelin and nerve fiber changes and impaired cognitive performance. The findings overturn the long-held view that oligodendrocytes are always supportive and suggest that targeting the NRF2 pathway, already used in multiple sclerosis drugs, could lead to new treatments for age-related cognitive decline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard